Researchers at University of California San Diego School of Medicine are recruiting eligible children between the ages of seven and fourteen years for a Phase III clinical trial to determine whether cannabidiol (CBD) reduces severe behavior problems in children with autism spectrum disorder.
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.
Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial to evaluate the safety and efficacy of an antiviral drug, DAS181, as a possible treatment for hospitalized patients with severe COVID-19.
The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.
An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.
Researchers at University of California San Diego School of Medicine and UC San Diego Health have launched a clinical trial to assess the safety and efficacy of convalescent plasma (CP) to prevent COVID-19 after a known exposure to the virus.
Medical cannabis is finally being put under the microscope, in a first-of-its-kind real world evidence study led by Dr. Hance Clarke, Toronto General Hospital. In the Medical Cannabis Real-World Evidence trial patients using the online portal created by Medical Cannabis by Shoppers, will know exactly what is in their product and its effectiveness.
A clinical trial conducted at Washington University School of Medicine in St. Louis and other sites has found evidence that the experimental drug tofersen lowers levels of a disease-causing protein in people with an inherited form of amyotrophic lateral sclerosis, or ALS, caused by mutations in the gene SOD1.
New research published in Nature Communications uses a technology first developed at the University of Miami Miller School of Medicine to enhance the oxygenation of cultured tissues that will likely be able to conduct real-time regeneration and development studies in the human pancreas.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently in clinical trials in oncology, and this research provides a strong rationale for evaluating the drugs in tumors that are not responsive to immune checkpoint therapy. The study was published in Science Translational Medicine.
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
- ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
Researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai have started recruiting participants for a new clinical trial to evaluate the safety, tolerability, and efficacy of a low dose of ketamine in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.
Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
New evidence upturns long-held medical practice, showing the efficacy of an intervention to prevent premature labor and miscarriage for mothers carrying twins.
Historically, half or more of people with type 1 diabetes develop kidney disease, which frequently progresses to kidney failure requiring hemodialysis or a kidney transplant for survival. Progression of kidney disease in type 1 diabetes is correlated with increased amounts of uric acid. A multi-institution randomized clinical trial of a drug used to control uric acid did not show the desired clinical benefits, but did give a very clear answer to an important scientific question.
MacNeal Hospital is the first hospital in Illinois to participate in a national, randomized clinical trial using daily vital signs and lung pressure measurement to manage patients with congestive heart failure (CHF). The PROACTIVE-HF trial utilizes a new monitoring system, coupled with a pressure sensor, implanted directly into a blood vessel in the lung. This system provides information that is recorded and transmitted over a cellular or Wi-Fi connection to a patient’s provider, allowing for medication changes, if necessary, to prevent further health deterioration or hospitalization.
The University of Chicago Medicine’s Center for Personalized Therapeutics is hosting a virtual summit from June 9 to July 1 to discuss interventional pharmacoeconomics.
Topics include the efficacy and safety of third-line treatment regimens in resource-limited settings, viral rebound rates after treatment interruption of modern ART, and whether a standardized frailty score can improve clinicians’ ability to estimate cardiovascular risk among older people with HIV.
The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.
Administering the MMR (measles, mumps, rubella) vaccine could serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection, say a team of experts in this week's mBio, a journal of the American Society for Microbiology.
Mount Sinai Health System is beginning the first clinical trial in the New York metropolitan region of an immune-boosting therapy in COVID-19 patients.
A major study investigating the effectiveness of liver perfusion as a technique to improve the function of donor livers that would have otherwise been rejected has shown that up to 7 in every 10 could be used after just 4-6 hours of the assessment.
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Results from a six-month, multi-site clinical trial called the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) Study Group have been published by the Journal of the American Medical Association (JAMA).
MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients' genomic profiles, with the aim of improving patient care.
A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient’s own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body’s immune system to attack any tumor cells that could cause disease relapse.
Researchers from Nationwide Children’s Hospital have published in JAMA Neurology results from the first four patients treated in the first clinical trial of systemic delivery of micro-dystrophin gene therapy in children with Duchenne muscular dystrophy (DMD) – and initial findings suggest that the therapy can provide functional improvement that is greater than that observed under the standard of care.
Researchers at UC San Diego School of Medicine, with colleagues elsewhere, will receive almost $19 million over five years for the fourth phase of the Vietnam Era Twin Study of Aging, which investigates cognition, aging and the risk for mild cognitive impairment and Alzheimer’s disease.
The University of Illinois at Chicago will soon test a vaccine for COVID-19. Expected to launch July 9, the trial — a phase 3 clinical study — will test the efficacy of a vaccine developed by biotech company Moderna.
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer
Atlantic Health System Cancer Care will continue its tradition of world-class medical education with its 2020 Annual Review in Oncology Virtual Symposium. The symposium, held virtually this year with free registration, will take place Saturday, June 27, 2020, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the Northeast’s leading cancer centers will summarize the latest advances in oncology, which have recently been presented at international conferences. The diverse range of topics should be of interest to surgeons, medical and radiation oncologists and other physicians, nurses and allied health professionals.
UVA Health and UVA Children’s are increasing access to the latest food allergy clinical trials and expanding their cutting-edge food-allergy research, following their selection to a national food-allergy clinical network.
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
The first convalescent plasma transfusion trial results from Houston Methodist have been published. Of the study’s 25 patients, 19 have improved and 11 discharged. With no adverse side effects caused by the therapy, the study concluded convalescent plasma is a safe treatment option for patients with severe COVID-19. This is the first peer-reviewed publication in the U.S. of convalescent plasma therapy results for COVID-19.
As a leading New Jersey academic medical center and member of Hackensack Meridian Health, Jersey Shore University Medical Center is able to provide its patients access to existing clinical trials and the latest medical techniques in a variety of specialties. Currently, the medical center is recruiting individuals who have been clinically diagnosed with COVID-19 or have laboratory test results showing they have COVID-19 antibodies to donate their blood and potentially assist patients in their recovery from the virus.
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.
Rutgers Cancer Institute expert discusses guarding data integrity for the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19.
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary IlluminoxTM technology platform.
The COVID Research Program is rapidly enrolling patients from New Jersey, which has one of the world’s highest concentrations of COVID-19 patients. Atlantic Health System offers a study sponsored by TScan Therapeutics, Inc., a leading T cell therapeutics company in Waltham, Massachusetts, focused on identifying the precise way the human immune system recognizes and responds to infections like COVID-19 or other diseases, like cancers. TScan has developed a novel technology that enables them to identify the natural targets of T cells.
A review of 56 randomized clinical trials finds that psychological and behavioral therapies may be effective non-drug treatments for reducing disease-causing inflammation in the body.
The University of Kentucky and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials.
Researchers at Tulane University School of Medicine identified a gene that causes an aggressive form of breast cancer to rapidly grow. More importantly, they have also discovered a way to “turn it off” and inhibit cancer from occurring. The animal study results have been so compelling that the team is now working on FDA approval to begin clinical trials and has published details in the journal Scientific Reports.
How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.
A $1M gift from the John and Mary Tu Foundation is accelerating the efforts of UC San Diego translational research virologist Davey Smith to increase the number of people tested for COVID-19, as well as develop new ways to track and treat the virus. Smith and his team are studying how the disease spreads to better inform contact tracing, as well as leading clinical trials to test new drugs for treatment of COVID-19.
The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce COVID-19 disease severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.
Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.